Preclinical Medications Screening in Alcohol Misuse, Negative Affect and Pain

开发治疗酒精使用障碍的药物是国家酒精滥用和酒精中毒研究所(NIAAA)的高度优先事项。NIAAA启动了一项临床前药物疗效测试计划，以促进发现治疗酒精使用障碍的药物靶点和先导化合物。该计划包括建立一个协调的基础设施和临床前实验室模型网络，可用于有效地筛选潜在的治疗药物。这项倡议的一个目标是促进在标准化的临床前模型中测试临床上可用的药物疗法以及新的专利化合物，这些模型捕捉到酒精使用障碍的关键因素。被认为是药物开发过程中的关键步骤，从这项临床前工作中产生的信息旨在为随后的努力提供信息，以推进人体实验室研究和受控临床试验中对候选化合物的评估。本合同的目的是在酒精滥用/酒精使用障碍的各个方面的临床前模型中对参考化合物、感兴趣的化合物和专有化合物进行盲法测试，包括过度饮酒、负面影响和疼痛。

Developing medications for treatment of alcohol use disorder is a high priority for the National Institute on Alcohol Abuse and Alcoholism (NIAAA). NIAAA has initiated a Preclinical Medication Efficacy Testing Program to foster discovery of medication targets and lead compounds to treat alcohol use disorder. This program included the establishment of a coordinated infrastructure and network of preclinical laboratory models that can be employed to effectively screen potential therapeutics. A goal of this initiative was to facilitate the testing of clinically available pharmacotherapies as well as novel proprietary compounds in standardized preclinical models that capture key elements of alcohol use disorder. Recognized as a critical step in the medications development process, information generated from this preclinical work is designed to both inform subsequent efforts to advance the evaluation of candidate compounds in human laboratory studies and controlled clinical trials. The purpose of this contract is to perform the blind testing of reference compounds, compounds of interest, and proprietary compounds in preclinical models of various aspects of alcohol misuse/alcohol use disorder including excessive alcohol consumption, negative affect, and pain.